Raymond James Begins Coverage on Black Diamond Therapeutics (NASDAQ:BDTX)

Raymond James initiated coverage on shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) in a report released on Wednesday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $20.00 price objective on the stock. Other research analysts also recently issued reports about the stock. Piper Sandler reaffirmed an overweight rating and […]

Leave a Reply

Your email address will not be published.

Previous post The Goldman Sachs Group Increases GeneDx (NASDAQ:WGS) Price Target to $32.00
Next post Willis Towers Watson Public (NASDAQ:WTW) Price Target Increased to $323.00 by Analysts at Keefe, Bruyette & Woods